The therapeutics of Alzheimer's disease: where we stand and where we are heading.
about
The antibody aducanumab reduces Aβ plaques in Alzheimer’s diseaseN-Terminal Extensions Retard Aβ42 Fibril Formation but Allow Cross-Seeding and Coaggregation with Aβ42Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication.Variance in brain volume with advancing age: implications for defining the limits of normality.Use of brain MRI atlases to determine boundaries of age-related pathology: the importance of statistical method.Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trialsBenzothiazole Amphiphiles Promote the Formation of Dendritic Spines in Primary Hippocampal Neurons.Ultrasound attacks Alzheimer's disease?Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage.Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease.Combating neurodegenerative disease with chemical probes and model systems.From Neurodegeneration to Brain Health: An Integrated Approach.Novel patented therapeutic approaches targeting the 37/67 kDa laminin receptor for treatment of cancer and Alzheimer's disease.Direct High Affinity Interaction between Aβ42 and GSK3α Stimulates Hyperphosphorylation of Tau. A New Molecular Link in Alzheimer's Disease?Alzheimer's disease: a report from the 7th Kuopio Alzheimer symposium.Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?An Alzheimer Disease-linked Rare Mutation Potentiates Netrin Receptor Uncoordinated-5C-induced Signaling That Merges with Amyloid β Precursor Protein Signaling.The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β-peptide folding into β-sheet to form oligomers.Chiral recognition in amyloid fiber growth.Twenty Years of Presenilins--Important Proteins in Health and Disease.Circadian Disruption Associated with Alzheimer's Disease.Stemming the Alzheimer tsunami: introduction to the special issue on reserve and resilience in Alzheimer's disease.Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias.Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials.Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation.Association between subclinical carotid atherosclerosis, hyperhomocysteinaemia and mild cognitive impairment.Gad67 haploinsufficiency reduces amyloid pathology and rescues olfactory memory deficits in a mouse model of Alzheimer's disease.ASM in Alzheimer's disease.Cyclic AC253, a novel amylin receptor antagonist, improves cognitive deficits in a mouse model of Alzheimer's diseaseeEF2K inhibition blocks Aβ42 neurotoxicity by promoting an NRF2 antioxidant response.Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.Calmodulin-like skin protein protects against spatial learning impairment in a mouse model of Alzheimer disease.Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.Functional Connectivity is Reduced in Early-stage Primary Progressive Aphasia When Atrophy is not Prominent.Evolvability of Amyloidogenic Proteins in Human Brain.Alzheimer's peptide amyloid-β, fragment 22-40, perturbs lipid dynamics.Sulforaphane rescues amyloid-β peptide-mediated decrease in MerTK expression through its anti-inflammatory effect in human THP-1 macrophages.
P2860
Q28005463-27CE6D3C-6671-4DCD-BB60-730EE2EDA948Q33626314-B5BBE9A0-C905-4A70-873C-D48A191E78DEQ33847755-D6EA2B86-20D6-41E9-AE12-128049BF120AQ35075666-C4FC8A23-B17D-41FB-9704-9AAB787FA328Q35646028-8283D6EC-3F7B-4DEB-A218-FEAC5207ACF9Q35695716-DAB8738F-D07C-444E-B465-ABD5270DE656Q35782753-2C518772-C3A6-436F-97F5-9910D52117E4Q35972293-8E7F2A19-D9AB-4843-BDB3-5BC7DB65DE47Q36241902-A09A6048-1A6C-497D-A8A6-8FAB8A7C2FE6Q36269285-E5A7BFC0-5395-4E3C-8FF6-258BC7436837Q37677012-F2119356-7A8D-43E5-9992-DF5C402BC80EQ38199617-86DD863E-FDA1-4233-A6D5-6888EFF594EFQ38261089-357BCA8E-CD9E-439D-99A3-7B98F784F31AQ38365566-1029A103-CF44-4897-BE83-4E2D737E215EQ38369288-CDAFF9B7-5DDA-427D-900F-532F2EC24A81Q38556871-65A72948-8CC6-49D2-BE3D-972A319C4406Q38610248-2F15508B-703C-4D18-B714-8ACC2FB53E22Q38675216-41EB6E11-5357-49ED-9EB0-0222242F24E4Q38779044-1219DCDC-6E96-497B-BD01-80F6B29DFA8AQ38806886-4FA50A33-923B-486B-8DF4-E6CA41FDBD21Q38901646-33273E3F-8661-46F4-B450-6EC44E7C1570Q38938820-89EFD4E9-E133-49B1-BCFF-5139F2AF5082Q39190597-328F968D-91A7-4698-A75B-9A3B1731C55BQ39302671-F51F98C2-F297-42C9-8584-1A6C830C1840Q39320824-D8DBC4FC-F9E2-4AC6-A6A8-4EA0C02FE1D6Q39346750-6B810AA2-16B9-481F-B7BA-E9E3129FDD02Q39753296-37147303-10C4-4720-B72A-F8D6564719BDQ40107032-6A11FB2F-C7BD-4E33-9B1E-62D783C420CBQ41183754-4F01FEFB-D373-4859-B1BF-A220BD2D4B28Q42373554-C3D845B7-453E-4A7F-BFE6-C9FBBEB7B5B4Q42552176-36B250FB-BF4B-4BFD-9E84-194C3F4030E9Q42656068-F3490902-93A5-4178-ABF1-8BD25F49DE83Q46476675-2BF6A85F-D415-4990-B09F-1EAF50A73341Q47345806-9641C44B-3D1C-41CE-9D72-B058708C2AEAQ47375015-6A01C6A0-85F3-4C35-ACF7-F845352CBA5BQ47566445-E2081F11-233F-4E9B-B37F-EC2463BFCC93Q48266212-DEF3A084-66AA-4E7B-BDBC-AD890CB95151Q50034432-7A0BE39C-73D7-4961-9B34-314E0FA446A4Q52145164-A7E51C95-8283-4F45-8F2A-647EC10EEC36Q53079574-F0320957-612B-4A83-AC0D-BC50C1F17235
P2860
The therapeutics of Alzheimer's disease: where we stand and where we are heading.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The therapeutics of Alzheimer's disease: where we stand and where we are heading.
@en
type
label
The therapeutics of Alzheimer's disease: where we stand and where we are heading.
@en
prefLabel
The therapeutics of Alzheimer's disease: where we stand and where we are heading.
@en
P2860
P356
P1433
P1476
The therapeutics of Alzheimer's disease: where we stand and where we are heading.
@en
P2093
Dennis J Selkoe
P2860
P304
P356
10.1002/ANA.24001
P577
2013-09-01T00:00:00Z